Cardiovascular Effects of Pancuronium and Vecuronium during High-Dose Fentanyl Anesthesia

1983 ◽  
Vol 62 (12) ◽  
pp. 1059???1064
Author(s):  
Markku Salmenper?? ◽  
Kaija Peltola ◽  
Olli Takkunen ◽  
Jussi Heinonen
1986 ◽  
Vol 11 (3) ◽  
pp. 337-348 ◽  
Author(s):  
Giovanni V. Ibba ◽  
Pierfranco Terrosu ◽  
Vittorio Franceschino ◽  
Gianna M. Contini

2015 ◽  
Vol 100 ◽  
pp. 148-156 ◽  
Author(s):  
Evelin Csepanyi ◽  
Attila Czompa ◽  
David Haines ◽  
Istvan Lekli ◽  
Edina Bakondi ◽  
...  

1995 ◽  
Vol 16 (5) ◽  
pp. 223-227 ◽  
Author(s):  
R. Crepaz ◽  
W. Pitscheider ◽  
R. Gadetti ◽  
C. Paganini ◽  
L. Gentili ◽  
...  

1989 ◽  
Vol 257 (1) ◽  
pp. H324-H329 ◽  
Author(s):  
M. J. Campagnole-Santos ◽  
D. I. Diz ◽  
R. A. Santos ◽  
M. C. Khosla ◽  
K. B. Brosnihan ◽  
...  

The amino terminal angiotensin heptapeptide, Asp-Arg-Val-Tyr-Ile-His-Pro [ANG-(1–7)], is the major product formed during incubation of 125I-labeled ANG I or 125I-labeled ANG II with homogenates obtained from canine dorsomedial medulla oblongata. To determine whether ANG-(1–7) has central-mediated cardiovascular effects, this heptapeptide was microinjected into the dorsal medulla of chloralose-urethan-anesthetized rats. Unilateral injections of ANG-(1-7) into the medial nucleus tractus solitarii caused depressor and bradycardic effects at doses between 0.1 and 12.5 ng. Similar hypotensive responses accompanied with bradycardia were produced by injections of ANG-(1–7) into the dorsal motor nucleus of the vagus. In both nuclei, the monophasic depressor responses elicited by ANG-(1–7) were qualitatively similar to those found with injections of ANG II. Biphasic depressor-pressor responses of variable magnitude were produced by the injection of either angiotensin peptide at a high dose (250 ng). Because ANG-(1–7) has no direct vascular or dipsogenic effects, our findings suggest important differences in the receptor requirements for vascular and neural tissue of the dorsal medulla. Moreover, the data support the concept of tissue specific formation and action of angiotensin peptides in the brain.


2012 ◽  
Vol 48 (4) ◽  
pp. 250-255 ◽  
Author(s):  
L. Noelani Reinker ◽  
Justine A. Lee ◽  
Lynn R. Hovda ◽  
Mark Rishniw

The purpose of this study was to review the medical records of dogs that were either suspected or known to have ingested large doses of pimobendan and to describe the clinical signs associated with pimobendan toxicosis. The database of Pet Poison Helpline, an animal poison control center located in Minneapolis, MN, was searched for cases involving pimobendan toxicosis from Nov 2004 to Apr 2010. In total, 98 cases were identified. Of those, seven dogs that ingested between 2.6 mg/kg and 21.3 mg/kg were selected for further evaluation. Clinical signs consisted of cardiovascular abnormalities, including severe tachycardia (4/7), hypotension (2/7), and hypertension (2/7). In two dogs, no clinical signs were seen. Despite a wide safety profile, large overdoses of pimobendan may present risks for individual pets. Prompt decontamination, including emesis induction and the administration of activated charcoal, is advised in the asymptomatic patient. Symptomatic and supportive care should include the use of IV fluid therapy to treat hypotension and address hydration requirements and blood pressure and electrocardiogram monitoring with high-dose toxicosis. Practitioners should be aware of the clinical signs associated with high-dose pimobendan toxicosis. Of the dogs reported herein, all were hospitalized, responded to supportive care, and survived to discharge within 24 hr of exposure.


Sign in / Sign up

Export Citation Format

Share Document